BioThrax与AV7909炭疽疫苗在66岁及以上成人中的评价
该2期临床研究在65岁以上成人中比较AV7909(含CpG佐剂)三种接种程序与BioThrax一种程序的安全性和免疫原性,共入组305人。结果显示AV7909免疫应答更强,尤以第1、15、29天三剂或第1、29天两剂为著;两种疫苗在老年人群中的应答均低于18-50岁人群。
要点
- AV7909在65岁以上成人中诱导的免疫应答强于BioThrax。
- 第1、15、29天三剂或第1、29天两剂AV7909程序血清保护率较高。
- 老年受试者对两种炭疽疫苗的应答均低于18-50岁人群。
核心结论
- 含CpG佐剂的AV7909疫苗有助于在65岁以上受试者中诱导更强的免疫应答。
- 鉴于第1、29天或第1、15、29天程序血清保护率高,可考虑在该人群中采用替代接种策略。
研究设计与样本
- 2期临床研究,评估AV7909三种接种程序与BioThrax一种接种程序在65岁以上成人中的安全性和免疫原性。
- 共入组305名受试者,通过血清保护率、毒素中和抗体滴度和抗保护性抗原ELISA滴度评估免疫原性。
- 试验注册号:clinicaltrials.gov NCT03518125。
主要发现
- 与BioThrax相比,AV7909在老年受试者中诱导更强的免疫应答,尤以第1、15、29天三剂或第1、29天两剂为著。
- 上述趋势在血清保护率(50%中和因子大于0.56的受试者百分比)和几何平均抗体滴度上均成立。
- 老年受试者对AV7909和BioThrax的应答均低于18-50岁人群。
关键数值与推荐
- 血清保护定义为50%中和因子大于0.56的受试者百分比。
- AV7909第1、15、29天三剂或第1、29天两剂程序血清保护率较高。
临床怎么用
- 在65岁以上成人中可优先考虑含CpG佐剂的AV7909及第1、29天或第1、15、29天程序以提升免疫应答。
- 评估老年人群炭疽暴露后预防时需注意其免疫应答低于18-50岁人群。
局限性
- 原文未报告具体血清保护率数值、几何平均滴度数值及安全性结果细节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple Anthrax vaccines are licensed or in development for post-exposure prophylaxis in individuals 18 to 65 years of age. No information exists on anthrax vaccines in populations over the age of 65. It is critical that we assess the capacity of anthrax vaccines to generate a protective immune response in older individuals. In this study, we compared BioThrax® to a formulation containing a CpG adjuvant (AV7909). METHODS: We conducted a Phase 2 clinical study to evaluate safety and immunogenicity of three vaccination schedules of the AV7909 vaccine candidate and one vaccination schedule of BioThrax® vaccine in adults over 65 years of age. A total of 305 subjects were enrolled to assess safety and immunogenicity by seroprotection rates, toxin neutralizing antibody titers, and anti-Protective Antigen ELISA titers. RESULTS: Compared to BioThrax, AV7909 elicited a more robust immune response in older subjects, especially with three doses of AV7909 at Days 1, 15, and 29, or two doses at Days 1 and 29. These trends were true with both seroprotection rates as defined by the percentage of subjects with 50 percent neutralization factors greater than 0.56, and geometric mean antibody titers. The responses to both AV7909 and BioThax were lower in older subjects compared to those aged 18-50. CONCLUSION: The immunogenicity data suggest that the CpG adjuvant in the AV7909 vaccine helps to elicit a more robust immune response in subjects over the age of 65. Alternative dosing strategies may be considered in this population given the high seroprotection rates with Day 1 and 29, or Day 1, 15, and 29 regimens. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT03518125.
引用
- Wolfe DN, Espeland EM, Gao Y, et al. Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older. Vaccine. 2020. PMID: 33129609. doi:10.1016/j.vaccine.2020.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。